Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

VWR International, LLC to Distribute Illumina’s qPCR Portfolio

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Dramatically expands sales reach within U.S. market.

Illumina, Inc. announced that VWR International, LLC, a global distributor of laboratory supplies and services, will distribute Illumina’s qPCR portfolio including the Eco™ Real-Time PCR System and NuPCR™ reagents within the United States, one of the world’s largest qPCR instrumentation markets. The agreement extends Illumina’s reach for its innovative Eco System and novel NuPCR probe-based technology into thousands of laboratories and facilities nationwide, by leveraging VWR’s 150 years of industry experience and its well-established distribution network.

“Complementing Illumina’s commercialization efforts with VWR’s talented team of sales and services representatives enables us to significantly expand promotion and support of both the Eco System and NuPCR reagents in molecular biology laboratories throughout the United States,” said Mark Lewis, Senior Vice President and General Manager of Illumina’s Molecular Biology and PCR Business. “We are very excited to join forces with VWR to accelerate adoption of our qPCR portfolio, particularly into the pharmaceutical and industrial markets where VWR has a strong presence.”

Real time PCR is a precise, highly sensitive PCR method with applications in basic research and diagnostics, where, for example, it is used for quantitation of gene expression targets, verification of array data, and pathogen detection. Illumina’s Eco Real-Time PCR System is an affordable, compact instrument that allows researchers to perform any qPCR application directly on their bench top and is an economical alternative to traditional large, expensive PCR instruments. The company’s novel, NuPCR probe-based qPCR technology is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies on the market today. It is compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation.

“Illumina’s qPCR portfolio adds tremendous value to our existing PCR solutions portfolio,” said Bill Molnar, Vice President of Category Management, Life Sciences, VWR. “Both of our companies are committed to enabling the world’s scientists to accelerate research. The addition of the Eco System and NuPCR reagents provides an essential element to our product line, empowering us to effectively support key customer segments.”

Customer orders for Illumina’s qPCR portfolio through VWR will be accepted starting December 1, 2012.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group, Illumina Collaborate
Almac Diagnostics today announced that it had entered into a collaboration with Illumina, Inc. to establish a framework for the development of next-generation sequencing (NGS)-based companion diagnostic assays.
Friday, November 13, 2015
Illumina Announces New $250 Million Share Repurchase Authorization
Company completed repurchase of $96 million under previous share repurchase program.
Tuesday, November 03, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Biomed Realty and Illumina Announce New Build-to-Suit Laboratory Building
New building to be located in scientific research park, Granta Park, and will serve as Illumina’s new European headquarters.
Friday, June 26, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina, Merck KGaA and Genea Form the Global Fertility Alliance
Global fertility alliance will identify and work on improvements of fertility-related laboratory processes.
Tuesday, June 09, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Antibiotics on Our Plates 'Could Lead to Health Catastrophe'
Two medical experts from The University of Queensland are urging China to curb its use of antibiotics in animals to avoid what could be a ‘major health catastrophe’ for humans.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos